3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
44
Pancreatic Neoplasms
37
Carcinoma, Non-Small-Cell Lung
37
Triple Negative Breast Neoplasms
28
Ovarian Neoplasms
20
Fallopian Tube Neoplasms
19
Lung Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
13
Neoplasm Metastasis
11
Uterine Cervical Neoplasms
8
Melanoma
7
Inflammatory Breast Neoplasms
7
Esophageal Squamous Cell Carcinoma
6
Breast Neoplasms, Male
6
Stomach Neoplasms
5
Cholangiocarcinoma
5
Brenner Tumor
5
Pancreatic Adenocarcinoma
4
Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Transitional Cell
4
Adenocarcinoma, Bronchiolo-Alveolar
4
Adenocarcinoma of Lung
4
Adenocarcinoma Of Esophagus
4
Urinary Bladder Neoplasms
3
Pleural Effusion, Malignant
3
Oropharyngeal Neoplasms
3
Nasopharyngeal Carcinoma
3
Mouth Neoplasms
3
Endometrial Neoplasms
3
Interventions
Fluorouracil
6
Cisplatin
4
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Capecitabine
3
dehydroftorafur
2
Specimen Handling
2
Mitomycin
2
Cetuximab
2
toripalimab
1
rocakinogene sifuplasmid
1
pembrolizumab
1
durvalumab
1
atezolizumab
1
Vaccines
1
VGX-3100
1
Taxes
1
Radiosurgery
1
Radiation
1
Platinum
1
Paclitaxel
1
Nivolumab
1
Mitozytrex
1
Mitomycins
1
MEDI0457
1
Ipilimumab
1
Immunoglobulin G
1
Fluorodeoxyglucose F18
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Anal Canal Carcinoma
×
Taxes
×
Clear all
NCT02560298
2023-06-22
InterAACT
Eastern Cooperative Oncology Group
Phase 2
Unknown
91 enrolled